AUS
NZ
UK
CA
USA
IND
Prescient therapeutics limited asx ptx
Prescient’s “BASKET” Approach Transforming Future Clinical Trials
January 30, 2020 06:54 PM AEDT| By Team Kalkine MediaClinical-stage oncology company, headquartered in Melbourne, Australia, Prescient Therapeutics (ASX:PTX) (“Prescient”), develops personalised medicines to defeat cancer taking an approach to address mutations that cause cancer. Current &...
Prescient Therapeutics' Remarkable 2019 Journey
January 03, 2020 02:49 PM AEDT| By Team Kalkine MediaA clinical-stage Oncology company, Prescient Therapeutics Limited (ASX: PTX) is primarily engaged in developing novel personalized cancer therapies targeting an array of challenging cancers with significant unmet need. Prescient’s approach...
Another Feather in Prescient’s Hat, Promising Efficacy Results from PTX-200 Phase 2a trial in HER2-Negative Breast Cancer
December 24, 2019 03:34 AM AEDT| By Team Kalkine MediaOf late, clinical stage oncology company, Prescient Therapeutics (ASX: PTX), focused on developing personalized medicines with an approach to address mutations causing cancer, has been under the spotlight for recent advancements in its clinical trial...
Prescient Takes Another Leap Forward, Unveils Promising Interim Results from PTX-200 Phase 1b Ovarian Cancer Trial
December 18, 2019 06:01 PM AEDT| By Team Kalkine MediaClinical stage oncology company engaged in developing personalised medicine approaches including targeted and cellular therapies to beat cancer, Prescient Therapeutics (ASX: PTX) has been gaining industry limelight for its advancing clinical trials....
Prescient Collaborates with Carina Biotech in Expansion into Exciting CAR-T Therapies
December 10, 2019 04:19 PM AEDT| By Team Kalkine MediaPrescient Therapeutics Limited (ASX: PTX) develops personalised medicine approaches to address mutations that cause cancer. The Company employs a targeted therapy approach to target individual tumour variability rather than the conventional one size...
Prescient Unveils Encouraging Results: Eradication of Cancer in Three Acute Myeloid Leukemia Patients
November 28, 2019 02:41 PM AEDT| By Team Kalkine MediaClinical-stage Oncology Company, Prescient Therapeutics Limited (ASX: PTX), that develops personalised medicine approaches to address mutations causing cancer. Prescient?s deep product pipeline include 2 clinical stage drugs with multiple shots on go...
A Walk-Through Prescient’s 2019 Achievements
November 25, 2019 07:29 PM AEDT| By Team Kalkine MediaPrescient Therapeutics Limited (ASX:?PTX) is involved in the development of breakthrough personalised cancer therapies via its novel anti-cancer drug candidates, PTX-100 and PTX-200, that have shown great promise in the treatment of a range of debili...
Prescient Therapeutics Collaborates with Carina Biotech for Development of Next Generation CAR-T Therapies
November 19, 2019 02:20 PM AEDT| By Team Kalkine MediaPrescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug development focused on new cancer drugs. The company is known for having a robust clinical pipeline with two drug candidates, PTX...
Shedding light on the Recent Fuss about RAS, Prescient released AusBiotech Presentation
November 11, 2019 02:42 PM AEDT| By Team Kalkine MediaWith a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX:?PTX) develops personalised medicines as potential novel cancer remedies targeting an array of debilitating cancers with significant unmet need. ?Prescient has a...
Prescient’s September 2019 Quarterly Update Unveils Encouraging Developments
November 06, 2019 03:29 PM AEDT| By Team Kalkine MediaPrescient Therapeutics Limited (ASX:?PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel targeted cancer therapies for a range of challenging cancers with significant unmet need. Prescient?s appro...
Prescient’s Leaders Have A Rich History Of Taking Drugs From Bench To Bedside
August 12, 2019 03:35 PM AEST| By Team Kalkine MediaPrescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on the mechani...
Opportunities In Personalised Medicine Industry On Prescient’s Radar
August 05, 2019 09:16 PM AEST| By Team Kalkine MediaClinical stage oncology company, Prescient Therapeutics Limited (ASX: PTX) is engaged in developing personalised medicines to treat a range of challenging cancers. The company is known for having one of the deepest clinical pipelines on ASX, with two...
Journey of Prescient Therapeutics in 2019
July 25, 2019 12:38 PM AEST| By Team Kalkine MediaPrescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company that works on mutation causing cancer. The existing product portfolio of the company includes two drug candidates, PTX 100 and PTX 200, under the development phase. Both...
Prescient Therapeutics’ Cancer Trials Backed By A Robust Product Portfolio
July 17, 2019 04:15 PM AEST| By Team Kalkine MediaClinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of developing a breakthrough to traditional therapies by its novel drug candidates that have shown great promise in the treatment of a range of cancers that h...
Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100
July 16, 2019 03:56 PM AEST| By Team Kalkine MediaOn 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in patients with multiple cancers. The trial would reportedly be led by one of the world?s leadi...
Prescient Therapeutics’ drug candidates addressing the mutations causing cancer
July 02, 2019 02:54 PM AEST| By Team Kalkine MediaClinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing cancer. The company?s mainstream operations are focused on th...
All that investors need to know about clinical stage oncology company, Prescient Therapeutics
May 28, 2019 03:44 PM AEST| By Team Kalkine MediaPrescient Therapeutics Limited (ASX: PTX), based in South Melbourne, Australia, is an oncology company (clinical-stage) that develops novel drugs and targeted therapies to treat specific mutations that stimulate cancer and thus, contribute to resista...
Prescient Therapeutics Announces The Receipts of R&D Tax Rebate
January 15, 2019 06:38 PM AEDT| By Team Kalkine MediaOn 15 January 2019, Prescient Therapeutics Limited (ASX: PTX) announced that the company had received Tax Incentive rebate on research and development for the financial year 2017-2018, amounting to $939,423. The R&D Tax Incentive is an Australian...
Advertise your brand on Kalkine Media